MobiHealth News April 12, 2021
The partners will use a new method of training AI known as transformer neural networks.
Silicon Valley giant NVIDIA is teaming up with pharma company AstraZeneca and the University of Florida on new artificial intelligence research projects aimed at boosting drug discovery and patient care.
This morning NVIDIA and AstraZeneca revealed a new drug-discovery model called MegaMoIBART, which is aimed at “reaction prediction, molecular optimization and de novo molecular generation.” MegaMoIBART will be deployable on NVIDIA’s platform for computational drug discovery, known as Clara Discovery, and will use a new kind of technology called transformer neural networks.
“They’ve only been available in the last couple of years. What is important to understand about them is it’s a two-stage process,” said...
Today's Sponsors
Today's Sponsor